<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892877</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0519</org_study_id>
    <nct_id>NCT02892877</nct_id>
  </id_info>
  <brief_title>The French National Reference Centre of GTD</brief_title>
  <acronym>French GTDC</acronym>
  <official_title>The French National Reference Centre of Gestational Trophoblastic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The French Gestational Trophoblastic Disease (GTD) centre has been set up and active by&#xD;
      registering, monitoring and treating women with GTD since november 1999. The aim is to&#xD;
      improve the management of trophoblastic disease in France.&#xD;
&#xD;
      About 850 new cases are registered each year and 140 women treated, mostly with chemotherapy&#xD;
      and surgery.&#xD;
&#xD;
      The center works as follow, based on a multidisciplinary approach. The policy is that patient&#xD;
      remains followed by her local physician, but can be seen and treated in the Center at demand&#xD;
      and that the registry is done on a voluntary basis.&#xD;
&#xD;
      Each administrative french area has a local expert team (oncologist and gynaecologist) who is&#xD;
      able to look after the patients with the help of the national reference center physicians&#xD;
      based in Lyon.&#xD;
&#xD;
        -  Once a doctor discovers a molar pregnancy, he contacts the center, with the agreement of&#xD;
           his patient, for an opinion, an advice or simply to report the case.&#xD;
&#xD;
        -  The center sends to the doctor the informed consent form to be signed by the patient, a&#xD;
           registering form and information about pathology for patient and physician, and first&#xD;
           guidelines based on initial pathology report.&#xD;
&#xD;
      The patient remains followed by her gynecologist, who stays her first interlocutor throughout&#xD;
      the whole process and she goes to her local laboratory for hCG monitoring;&#xD;
&#xD;
        -  A letter is sent to the initial pathology laboratory that originally carried the&#xD;
           diagnosis of molar pregnancy to require slide sending to the pathologist referral center&#xD;
           (9 experts with a specific pathologist national network) that centrally review initial&#xD;
           diagnosis.&#xD;
&#xD;
        -  In the mean time, the data manager collects weekly hCG values to establish a follow-up&#xD;
           chart. The physician is regularly informed by mail of the hCG evolution.&#xD;
&#xD;
        -  The local physician is contacted in case of modification of the diagnosis by the&#xD;
           pathologist expert. The center informs him about length and monitoring methodology.&#xD;
&#xD;
        -  Emails or letters are sent at each step of the management (at inclusion, at hCG&#xD;
           negativation, and at the end of hCG follow-up).&#xD;
&#xD;
        -  In case of abnormal hCG evolution (raise, plateauing or positivity at 6 months,) or if a&#xD;
           neoplasia is anatomopathologically diagnosed (choriocarcinoma, PSTT or ETT), physician&#xD;
           is immediately contacted by phone or email by referent gynaecologist. A complete work up&#xD;
           including pelvic US with Doppler, pelvic MRI, thoraco-abdominal CT-scan with chest&#xD;
           radiography if pulmonary nodules are present and brain MRI, is planned to determine the&#xD;
           adequate treatment.&#xD;
&#xD;
      Very briefly, based on imaging results, FIGO stade and score are calculated to determine the&#xD;
      risk. In case of low-risk, a monochemotherapy is settled, while a polychemotherapy is started&#xD;
      in case of high-risk disease.&#xD;
&#xD;
      The investigators have developped specific expertise at key levels of diagnosis, management,&#xD;
      follow-up, fertility preservation and treatment.&#xD;
&#xD;
      Assignments :&#xD;
&#xD;
        -  Registration and monitoring post diagnosis of complete or partial molar pregnancy,&#xD;
           choriocarcinoma,PSTT, ETT, atypical placental site nodules&#xD;
&#xD;
        -  Histopathological analysis and genetics services&#xD;
&#xD;
        -  Measurement of human chorionic gonadotrophin (hCG) isoforms&#xD;
&#xD;
        -  Complex gynaecological surgery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 1999</start_date>
  <completion_date type="Anticipated">November 2029</completion_date>
  <primary_completion_date type="Anticipated">November 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Agreement (yes or no) between local and pathologists in case of diagnosis of trophoblastic deseases</measure>
    <time_frame>18 months</time_frame>
    <description>trophoblastic deseases can be partial or complete molal pregnancy, choriocarcinoma, , placental site trophoblastic tumors (PSTT), epithelioid trophoblastic tumors (ETT), atypical placental site nodule.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">25500</enrollment>
  <condition>Neoplasm, Trophoblastic</condition>
  <condition>Gestational Trophoblastic Disease</condition>
  <condition>Hydatidiform Mole</condition>
  <condition>Hydatidiform Mole, Invasive</condition>
  <arm_group>
    <arm_group_label>Complete Hydatidiform mole and Partial Hydatidiform mole</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Invasive mole</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Choriocarcinoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-molar neoplasia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Placental Site Trophoblastic and Epithelioid Tumor</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient diagnosed with trophoblastic disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients are eligible if they have a histologically proven trophoblastic disease, or a&#xD;
             diagnosis of gestational trophoblastic neoplasia done on an abnormal evolution of hCG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Golfier, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre National de Référence des maladies trophoblastiques Centre Hospitalier Lyon Sud - Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François Golfier, Pr</last_name>
    <phone>(0)4 78 86 66 78</phone>
    <phone_ext>+33</phone_ext>
    <email>francois.golfier@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Touria Hajri</last_name>
    <phone>(0)4 78 86 66 78</phone>
    <phone_ext>+33</phone_ext>
    <email>touria.hajri@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre des Maladies Trophoblastiques Centre Hospitalier Lyon Sud-Bâtiment 3B-2ème étage, 165 Chemin du Grand Revoyet</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Golfier, Pr</last_name>
      <phone>(0)4 78 86 66 78</phone>
      <phone_ext>+33</phone_ext>
      <email>francois.golfier@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Touria Hajri</last_name>
      <phone>(0)4 78 86 66 78</phone>
      <phone_ext>+33</phone_ext>
      <email>touria.hajri@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.mole-chorio.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Complete Hydatidiform mole</keyword>
  <keyword>Partial Hydatidiform mole</keyword>
  <keyword>Invasive mole</keyword>
  <keyword>Choriocarcinoma</keyword>
  <keyword>Post-molar neoplasia</keyword>
  <keyword>Placental Site Trophoblastic Tumor (PSTT)</keyword>
  <keyword>Epithelioid Trophoblastic Tumor (ETT)</keyword>
  <keyword>hCG follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydatidiform Mole</mesh_term>
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
    <mesh_term>Hydatidiform Mole, Invasive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

